Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects

Histology and Histopathology

Volumn 18, Issue 2, 2003, Pages 495-507

  Nicholas, T W ^a   Read, S B ^a   Burrows, F J ^b,c   Kruse, Carol A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BIOGEN   (United States)

Author keywords

Bystander effect; Connexin; Gap junctions; Glioma; Suicide gene therapy

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APIGENIN; CONNEXIN 26; CONNEXIN 32; CONNEXIN 43; CONNEXIN 45; CYTOKINE; DRUG METABOLITE; GANCICLOVIR; GAP JUNCTION PROTEIN; MEVINOLIN; PROTEIN BCL 2; RETINOIC ACID; THYMIDINE KINASE;

BRAIN EDEMA; BRAIN TUMOR; BYSTANDER EFFECT; CELL COMMUNICATION; CELL DEATH; CELL JUNCTION; CELL POPULATION; CELL STRAIN HT29; CELL TYPE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COCULTURE; COLORECTAL TUMOR; CONFUSION; DRUG POTENTIATION; GLIOMA; HEADACHE; HERPES SIMPLEX VIRUS; HUMAN; IN VITRO STUDY; LETHAL DOSE; MENINGITIS; MONOTHERAPY; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; TUMOR CELL LINE; VIRAL GENE THERAPY;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; BYSTANDER EFFECT; CONNEXINS; GANCICLOVIR; GAP JUNCTIONS; GENE THERAPY; HUMANS; SIMPLEXVIRUS; THYMIDINE KINASE;

HERPES; MAMMALIA; SIMPLEXVIRUS;

EID: 0037378721     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Abrams C.K. and Bennett M.V.L. (2000). Hereditary human diseases caused by connexin mutations. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Perrachia C. (ed). Academic Press. San Diego. pp 423-459.
2. Bansal K. and Engelhard H.H. (2000). Gene therapy for brain tumors. Curr. Oncol. Reports 2, 463-472.
3. Barba D., Hardin J., Sadelain M. and Gage F.H. (1994). Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352.
4. Bai S., Du L., Liu W., Whittle I.R. and He L. (1999). Tenative novel mechanism of the bystander effect in glioma gene therapy with HSV-TK/GCV system. Biochem. Biophys. Res. Commun. 259, 455-459.
5. Bi W.L., Kim Y.G., Feliciano E.S., Pavelic L., Wilson K.M., Pavelic Z.P. and Stambrook P.J. (1997). An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. 4, 246-252.
6. Bi W.L., Parysek L.M., Warnick R. and Stambrook P.J. (1993). In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
7. Boucher P.D., Ruch R.J. and Schewach D.S. (1998). Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther. 9, 801-814.
8. Brink P.R., Valiunas V. and Christ G.J. (2000). Homotypic, heterotypic, and heteromeric gap junctions channels. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Perracchia C. (ed). Academic Press. San Diego. pp 43-60.
9. Burrows F.J., Gore M., Smiley W.R., Kanemitsu M.Y., Jolly D.J., Read S.B., Nicholas T. and Kruse C.A. (2002). Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. 9, 87-95.
10. Cirenei N., Colombo B.M., Mesnil M., Benedetti S., Yamasaki H. and Finocchiaro G. (1998). In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: Consequences for HSVtk/GCV anticancer gene therapy. Gene Ther. 5, 1221-1226.
11. Carrio M., Romagosa A., Mercade E., Mazo A., Nadal M., Gomez-Foix A. and Fillat C. (1999). Enhanced pancreatic tumor regression by a combination of adenovirus and retro-mediated delivery of the Herpes simplex virus thymidine kinase gene. Gene Ther. 6, 547-553.
12. Carrio M., Mazo A., Lopez-Iglesias C., Estivill X. and Fillat C. (2001). Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells resulting in variable efficiency on the bystander killing: Implications for gene therapy. Int. J. Cancer 94, 81-88.
13. CBTRUS (2000). Statistical Report: Primary Brain Tumors in the United States, 1992-1997. Published by the Central Brain Tumor Registry of the United States.
14. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H. and Blaese R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
15. Denning C. and Pitts J.D. (1997). Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther. 8, 1825-1835.
16. Dewey R.A., Morrissey G., Cowsill C.M., Stone D., Bolognani F., Dodd N.J.F., Southgate T.D., Klatzmann D., Lassmann H., Castro M.G. and Lowesntein P.R. (1999). Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nature Med. 5, 1256-1263.
17. Dickerman L.H. and Tischfield J.A. (1978). Comparative effects of adenine analogs upon metabolic cooperation between hamster cells with different levels of adenine phosphoribosyltransference activity. Mutat. Res. 49, 83-94.
18. Dilber M.S., Abedi M.R., Christensson B., Bjorkstrand B., Kidder G.M., Naus C.C.G., Gahrton G. and Smith C.I.E. (1997). Gap junctions promote the bystander effect of herpes simplex virus kinase in vivo. Cancer Res. 57, 1523-1528.
19. Dilber M.S. and Gahrton G. (2001). Suicide gene therapy: Possible applications in haematopoietic disorders. J. Intern. Med. 249, 359-367.
20. Di Meco F., Benedetti S., Colombo M.P. and Finocchiaro G. (1997). Perspectives for the gene therapy of malignant gliomas by suicide gene transfer. J. Neurosurg. Sci. 41, 227-234.
21. Drake R.R., Pitlyk K., McMasters R.A., Mercer K.E., Young H. and Moyer M.P. (2000). Connexin-independent ganciclovir-mediated killing conferred on bystander effect-resistant cell lines by a herpes simplex virus-thymidine kinase-expressing colon cell line. Mol. Ther. 2, 515-523.
22. Du L., Bai S., Whittle I.R. and He L. (1998). Another mechanism causing the bystander effect besides the gap junction's role during the glioma gene therapy with HSV-TK/GCV system. Adv. Exp. Med. Biol. 451, 133-138.
23. Duflot-Dancer A., Mesnil M. and Yamasaki H. (1997). Dominant-negative abrogation of connexin-mediated cell growth by mutant connexin genes. Oncogene 15, 2151-2158.
24. Duflot-Dancer A., Piccoli C., Rolland A., Yamasali H. and Mesnil M. (1998). Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in Herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 5, 1372-1378.
25. Elenes S. and Moreno A.P. (2000). Heteromultimeric gap junction channels and cardiac disease. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Peracchia C. (ed). Academic Press. San Diego. pp 61-93.
26. Elshami A.A., Saavedra A., Zhang H., Kucharczuk J.C., Spray D.C., Fishman G.I., Amin K.M., Kaiser L.R. and Albelda S.M. (1996). Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85-92.
27. Engelhard H.H. (2000). Gene therapy for brain tumors: The fundamentals. Surg. Neurol. 54, 3-9.
28. Estin D., Li M., Spray D. and Wu J.K. (1999). Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery 44, 361-368.
29. Fick J., Barker F.G. II., Dazin P., Westphale E.M., Beyer E.C. and Israel M.A. (1995). The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92, 11071-11075.
30. Freeman S.M. (2000). Suicide gene therapy. Adv. Exp. Med. Biol. 465, 411-422.
31. Freeman S.M., Abboud C.N., Whartenby K.A. and Abraham G.N. (1993). The bystander effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5284.
32. Freeman S.M., Ramesh R., Shastri M., Munshi A., Jensen A.K. and Marrogi A.J. (1995). The role of cytokines in mediating the bystander effect using HSV-TK xenogenic cells. Cancer Lett. 92, 167-174.
33. Fujimoto W.Y., Subak-Sharpe J.H. and Seegmiller J.E. (1971). Hypoxanthine-guanine phosphoribosyltransferase deficiency: Chemical agents selective for mutant or normal cultured fibroblasts in mixed and heterozygote cultures. Proc. Natl. Acad. Sci. USA 68, 1516-1519.
34. Gagandeep S., Brew R., Green B., Christmas S.E., Klatzmann D., Poston G.J. and Kinsella A.R. (1996). Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 3, 83-88.
35. Gerschenson L.E. and Rotello R.J. (1992). Apoptosis: A different type of cell death. FASEB J. 6, 2450-2455.
36. Hamel W., Magnelli L., Chiarugi V.P. and Israel M.A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56, 2697-2702.
37. Hossain M.Z., Ao P. and Boynton A.L. (1998). Rapid disruption of gap junctional communication and phosphorylation of connexin42 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J. Cell. Physiol. 174, 66-77.
38. Howard M.K., Kershaw T., Gibb B., Storey N., MacLean AR., Zeng B-Y., Tel B.C., Jenner P., Brown SM., Woolf C.J., Anderson P.N., Coffin R.S. and Latchman D.S. (1998). High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Gene Ther. 5, 1137-1147.
39. Huang R.P., Fan Y., Hossain M.Z., Peng A., Zeng Z.L. and Boynton A.L. (1998). Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res. 58, 5089-5096.
40. Huang R.P., Hossain M.Z., Sehgal A. and Boynton A.L. (1999). Reduced connexin43 expression in high-grade human brain glioma cells. J. Surg. Oncol. 70, 21-24.
41. Huang R.P., Hossain M.Z., Huang R., Gano J., Fan Y. and Boynton A.L. (2001). Connexin 43 (CX43) enhances chemotherapy - Induced apoptosis in human glioblastoma cells. Int. J. Cancer 92, 130-138.
42. Ishii-Morita H., Agbaria R., Mullen C.A., Hirano H., Koeplin D.A., Ram Z., Oldfield E.H., Johns D.G. and Blaese R.M. (1997). Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4, 244-251.
43. Kianmanesh A.R., Perrin H., Panis Y., Fabre M., Nagy H.J., Houssin D. and Klatzmann D. (1997). A "distant" bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8, 1807-1814.
44. Kim Y.G., Bi W., Feliciano E.S., Drake R.R. and Stambrook P.J. (2000). Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther. 7, 240-246.
45. Klatzmann D., Valery C.A., Bensimon G., Marro B., Boyer O., Mokhtari K., Diquet B., Saltzmann J.L., Philippon J. (1998). A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum. Gene Ther. 9, 2595-2604.
46. Kruse C.A., Lamb C., Hogan S., Smiley W.R., Kleinschmidt-DeMasters B.K. and Burrows F.J. (2000). Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther. 7, 118-127.
47. Kruse C.A., Roper M.D., Kleinschmidt-DeMasters B.K., Banuelos S.J., Smiley W.R., Robbins J.M. and Burrows F.J. (1997). Purified herpes simplex thymidine kinase Retrovector™ particles. I. In vivo characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther. 4, 118-128.
48. Kawamura K., Bahar R., Namba H., Seimiya M., Takenaga K., Hamada H., Sakiyama S. and Tagawa M. (2001). Bystander effect in uracil phosphoribosyltransferase/5 -fluorouracil-mediated suicide gene therapy is correlated with the level of intercellular communication. Int. J. Oncol. 18, 117-120.
49. Kuriyama S., Kikukawa M., Masui K., Okuda H., Nakatani T., Akahane T., Mitoro A., Tominaga K., Tsujinoue H., Yoshiji H., Okamoto S., Fukui H. and Ikenaka K. (1999). Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int. J. Cancer 83, 374-380.
50. Laird D.W., Fistouris P., Batist G., Alpert L., Huynh H.T., Carystinos G.D. and Alaoui-Jamali M.A. (1999). Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res. 59, 4104-4110.
51. Lal S., Lauer U.M., Niethammer D., Beck J.F. and Schlegel P.G. (2000). Suicide genes: Past, present and future perspectives. Immunol. Today 21, 48-54.
52. Lam P.Y.P and Breakefield X.O. (2001). Potential of gene therapy for brain tumors. Hum. Gene Ther. 10, 777-787.
53. Lowenstein W.R. and Kanno Y. (1966). Intercellular communication and the control of tissue growth: Lack of communication between cancer cells. Nature 209, 1248-1249.
54. McMasters R.A., Saylors R.L., Jones K.E., Hendrix M.E., Moyer M.P. and Drake R.R. (1998). Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum. Genet Ther. 9, 2253-2261.
55. Marconi P., Tamura M., Moriuchi S., Krisky D.M., Niranjan A., Goins W.F., Cohen J.B. and Glorioso J.C. (2000). Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol. Ther. 1, 71-81.
56. Mesnil M. and Yamasaki H. (2000). Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res. 60, 3989-3999.
57. Mesnil M., Piccoli C., Tiraby G., Willecke K. and Yamasaki H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93, 1831-1835.
58. Mesnil M., Piccoli C. and Yamasaki H. (1997). A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res. 57, 2929-2932.
59. Moolten F.L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradygm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
60. Moolten F.L. and Wells J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
61. Murray S.A., Davis K., Fishman L.M. and Bornstein S.R. (2000). a1 connexin 43 gap junctions are decreased in human adrenocortical tumors. J. Clin. Endocrinol. Metabol. 85, 890-895.
62. Namba H., Iwadate Y., Kawamura K., Sakiyama S. and Tagawa M. (2001). Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene Ther. 8, 414-420.
63. Naus C.C., Elisevich K., Zhu D., Belliveau D.J. and Del Maestro R.F. (1992). In vivo growth of C6 glioma cells transfected with connexin43 cDNA. Cancer Res. 52, 4208-4213.
64. Niculescu-Duvas I., Spooner R., Marais R. and Springer C.J. (1998). Gene-directed enzyme prodrug therapy. Bioconjugate Chem. 9, 4-22.
65. Okada T., Shah M., Higginbotham J.N., Li Q., Wildner O., Walbridge S., Oldfield E., Blaese R.M. and Ramsey W.J. (2001). AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther. 8, 1315-1322.
66. Oldfield E.H., Ram Z., Culver K.W., Blaese R.M., DeVroom H.L. and Anderson W.F. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
67. Packer R.J., Raffel C., Villablance J.G., Tonn J-G., Burdach S.E., Burger K., LaFond D., McComb G., Cogen P.H., Vezina G. and Kapcala L.P. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92, 249-254.
68. Park J.Y., Elshami A.A., Amin K., Rizk N., Kaiser L.R. and Albelda S.M. (1997). Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Ther. 4, 909-917.
69. Pope I.M., Poston G.J. and Kinsella A.R. (1997). The role of the bystander effect in suicide gene therapy. Eur. J. Cancer 33, 1005-1016.
70. Princen F., Robe P., Lechanteur C., Mesnil M., Rigo J.M., Gielen J., Mervill M.P. and Bours V. (1999). A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. Clin. Cancer Res. 5, 3639-3644.
71. Princen F., Robe P., Gros D., Jarry-Guichard T., Gielen J., Merville M.P. and Bours V. (2001). Rat gap junction connexin-30 inhibits proliferation of glioma cell lines. Carcinogenesis 22, 507-513.
72. Qiao J., Black M.E. and Caruso M. (2000). Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum. Gene Ther. 11, 1569-1576.
73. Rainov N.G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389-2401.
74. Ram Z., Culver K.W., Oshiro E.M., Viola J.J., DeVroom H.L., Otto E., Long Z., Chiang Y., McGarrity G.J., Muul L.M., Katz D., Blaese R.M. and Oldfield E.H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 3, 1354-1361.
75. Ram Z., Walbridge S., Shawker T., Culver K.W., Blaese M. and Oldfield E.H. (1994). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81, 256-260.
76. Ramesh R., Marrogi A.J., Munshi A., Abboud C.N. and Freeman S.M. (1996). In vivo analysis of the "bystander effect": A cytokine cascade. Exp. Hematol. 24, 829-838.
77. Ramesh R., Munshi A., Marrogi A.J. and Freeman S.M. (1999). Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int. J. Cancer 80, 380-386.
78. Robe P.A., Princen F., Martin D., Malgrange B., Stevenaert A., Moonen G., Gielen J., Merville M.P. and Bours V. (2000). Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system. Biochem. Pharmacol. 60, 241-240.
79. Rose B., Mehta P.P. and Loewenstein W.R. (1993). Gap-junction protein gene suppresses tumorigenicity. Carcinogenesis 14, 1073-1075.
80. Rosolen A., Frascella E., Di Francesco C., Todesco A., Petrone M., Mehtali M., Zacchello F., Zanesco L. and Scarpa M. (1997). In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther. 5, 113-120.
81. Rubsam L.Z., Boucher P.D., Murphy P.J., Kukuruga M. and Shewach D.S. (1999). Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59, 669-675.
82. Ruch R.J. (2000). Role of gap junctions in cellular growth control and neoplasia: Evidence and mechanisms. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Peracchia C. (ed). Academic Press. San Diego. pp 535-554.
83. Sasaki M. and Plate K.H. (1998). Gene therapy of malignant glioma: Recent advances in experimental and clinical studies. Ann. Oncol. 9, 1155-1166.
84. Shand N., Weber F., Mariani L., Berstein M., Gianella-Borradori A., Long Z., Sorensen A.G. and Barbier N. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum. Gene Ther. 10, 2325-2335.
85. Shinoura N., Chen L., Wani M.A., Kim Y.G., Larson J.J., Warnick R.E., Simon M., Menon A.G., Bi W.L. and Stambrook P.J. (1996). Protein and messenger RNA expression of connexin43 in astrocytomas: Implications in brain tumor gene therapy. J. Neurosurg. 84, 839-846.
86. Singh S., Cunningham C., Buchanan A., Jolly D.J. and Nemunaitis J. (2001). Toxicity assessment of intratumoral injection of the Herpes simplex type 1 thymidine kinase gene delivered by retrovirus in patients with refractory cancer. Mol. Ther. 4, 157-160.
87. Sosinsky G. (2000). Gap junction structure: New structures and new insights. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Peracchia C. (ed). Academic Press. San Diego. pp 1-22.
88. Spray D.C., Kojima T., Scemes E., Suadicani S.O., Gao Y., Zhao S. and Fort A. (2000). "Negative" physiology: What connexin-deficient mice reveal about the functional roles of individual gap junction proteins. In: Current Topics in Membranes. Vol. 49. Gap Junctions: Molecular Basis of Cell Communication in Health and Disease. Peracchia C. (ed). Academic Press. San Diego. pp 509-533.
89. Sturtz F.G., Waddell K., Shulok J., Chen X., Caruso M., Sanson M., Snodgrass H.R. and Platika D. (1997). Parameters influencing the efficiency of the thymidine kinase/ganciclovir strategy in human glioblastoma cell lines. Stereotact. Funct. Neurosurg. 68, 252-257.
90. Subak-Sharpe H., Burk R.R. and Pitts J.D. (1969). Metabolic cooperation between biochemically marked mammalian cells in tissue culture. J. Cell Sci., 4, 353-367.
91. Suhr S.T. and Gage F.T. (1999). Gene therapy in the central nervous system: The use of recombinant retroviruses. Arch Neurol. 56, 287-292.
92. Tamura M., Ikenaka K., Tamura K., Yoshimatsu T., Miyao Y., Kishima H. and Mabuchi E. (1998). Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors. Gene Ther. 5, 1698-1704.
93. Tanaka M., Fraizer G.C., De La Cerda J., Cristiano R.J., Liebert M. and Grossman H.B. (2001a). Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther. 8, 139-148.
94. Tanaka T., Yamasaki H. and Mesnil M. (2001b). Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. Int. J. Cancer 91, 538-542.
95. Todryk S., Melcher A., Bottley G., Gough M. and Vile R. (2001). Cell death associated with genetic prodrug activation therapy of colorectal cancer. Cancer Lett. 174, 25-33.
96. Touraine R.L., Ishii-Morita H., Ramsey W.J. and Blaese R.M. (1998a). The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5, 1705-1711.
97. Touraine R.L., Vahanian N., Ramsey W.J. and Blaese M. (1998b). Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther. 9, 2385-2391.
98. Trask T.W., Trask R.P., Aguilar-Cordova E., Shine H.D., Wyde P.R., Goodman J.C., Hamilton W.J., Rojas-Martinez A., Chen S-H., Woo S.L.C. and Grossman R.G. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1, 195-203.
99. Vrionis F.D., Wu J.K., Qi P., Waltzman M., Cherington V. and Spray D.C. (1997). The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 4, 577-585.
100. Weyerbrock A. and Oldfield E.H. (1999). Gene transfer technologies for malignant gliomas. Curr. Opin. Oncol. 11, 168-173.
101. Wilgenbus K.K., Kirkpatrick C.J., Knuechel R., Willecke K. and Traub O. (1992). Expression of Cx26, Cx32, and Cx43 gap junction proteins in normal and neoplastic human tissues. Int. J. Cancer 51, 522-529.
102. Wu J.K., Cano W.G., Meylaerts S.A.G., Qi P., Vrionis F. and Cherington V. (1994). Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35, 1094-1103.
103. Yamasaki H., Krutovskikh V., Mesnil M., Tanaka T., Zaidan-Dagli M.L. and Omori Y. (1999). Role of connexin (gap junction) genes in cell growth control and carcinogenesis. C. R. Acad. Sci. III. 322, 151-159.
104. Yang L., Chiang Y., Lenz H.J., Danenberg K.D., Spears C.P., Gordon E.M., Anderson W.F. and Parekh D. (1998). Intercellular communication mediated the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther. 9, 719-728.
105. Yano T., Hernandez-Blazquez F.J., Omori Y. and Yamasaki H. (2001). Reduction of malignant phenotype of HEPG2 cell is associated with the expression of connexin 26 but not connexin 32. Carcinogenesis 22, 1593-1600.
106. Zhang W., Couldwell W.T., Simard M.F., Song H., Lin J.H.C. and Nedergaard M. (1999). Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res. 59, 1994-2003.